Literature DB >> 22633296

Diabetic cardiomyopathy: myth or reality?

Laura Ernande1, Geneviève Derumeaux.   

Abstract

Diabetes mellitus has reached an epidemic level worldwide. Cardiovascular diseases are the primary cause of death in diabetic patients, not only because of coronary artery disease and associated hypertension but also because of a direct adverse effect of diabetes on the heart, independent of other potential aetiological factors. However, the existence of this 'diabetic cardiomyopathy' remains controversial. We aimed to review current evidence for the existence of diabetic cardiomyopathy, focusing particularly on the clinical setting.
Copyright © 2012 Elsevier Masson SAS. All rights reserved.

Entities:  

Mesh：

Year:  2012        PMID： 22633296     DOI： 10.1016/j.acvd.2011.11.007

Source DB:  PubMed          Journal:  Arch Cardiovasc Dis        ISSN： 1875-2128            Impact factor:   2.340


  22 in total

Review 1.  Echocardiographic feature of diabetic cardiomyopathy: where are we now?

Authors:  Kazuaki Negishi
Journal:  Cardiovasc Diagn Ther       Date:  2018-02

Review 2.  Heart failure: an underestimated therapeutic target in diabetes.

Authors:  Nikolaus Marx
Journal:  Cardiovasc Endocrinol Metab       Date:  2018-02-14

Review 3.  Complex roads from genotype to phenotype in dilated cardiomyopathy: scientific update from the Working Group of Myocardial Function of the European Society of Cardiology.

Authors:  Antoine Bondue; Eloisa Arbustini; Anna Bianco; Michele Ciccarelli; Dana Dawson; Matteo De Rosa; Nazha Hamdani; Denise Hilfiker-Kleiner; Benjamin Meder; Adelino F Leite-Moreira; Thomas Thum; Carlo G Tocchetti; Gilda Varricchi; Jolanda Van der Velden; Roddy Walsh; Stephane Heymans
Journal:  Cardiovasc Res       Date:  2018-08-01       Impact factor: 10.787

Review 4.  [Diabetes and heart failure : Update 2017].

Authors:  K Schütt; N Marx
Journal:  Herz       Date:  2017-05       Impact factor: 1.443

Review 5.  Insulin resistance and hyperinsulinaemia in diabetic cardiomyopathy.

Authors:  Guanghong Jia; Vincent G DeMarco; James R Sowers
Journal:  Nat Rev Endocrinol       Date:  2015-12-18       Impact factor: 43.330

6.  Mammalian target of rapamycin (mTOR) inhibition with rapamycin improves cardiac function in type 2 diabetic mice: potential role of attenuated oxidative stress and altered contractile protein expression.

Authors:  Anindita Das; David Durrant; Saisudha Koka; Fadi N Salloum; Lei Xi; Rakesh C Kukreja
Journal:  J Biol Chem       Date:  2013-12-26       Impact factor: 5.157

7.  Silent diabetic cardiomyopathy in everyday practice: a clinical and echocardiographic study.

Authors:  Brane Loncarevic; Danijela Trifunovic; Ivan Soldatovic; Bosiljka Vujisic-Tesic
Journal:  BMC Cardiovasc Disord       Date:  2016-11-29       Impact factor: 2.298

Review 8.  PPARs modulate cardiac metabolism and mitochondrial function in diabetes.

Authors:  Ting-Wei Lee; Kuan-Jen Bai; Ting-I Lee; Tze-Fan Chao; Yu-Hsun Kao; Yi-Jen Chen
Journal:  J Biomed Sci       Date:  2017-01-10       Impact factor: 8.410

9.  Evolution of subclinical myocardial dysfunction detected by two-dimensional and three-dimensional speckle tracking in asymptomatic type 1 diabetic patients: a long‑term follow-up study.

Authors:  Anne Ringle; Anne Dornhorst; Michaela B Rehman; Cristina Ruisanchez; Petros Nihoyannopoulos
Journal:  Echo Res Pract       Date:  2017-12

10.  Subclinical Alterations of Cardiac Mechanics Present Early in the Course of Pediatric Type 1 Diabetes Mellitus: A Prospective Blinded Speckle Tracking Stress Echocardiography Study.

Authors:  Kai O Hensel; Franziska Grimmer; Markus Roskopf; Andreas C Jenke; Stefan Wirth; Andreas Heusch
Journal:  J Diabetes Res       Date:  2015-12-29       Impact factor: 4.011
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.